SCHEMBL23218238

SCHEMBL23218238

NCc1cccc(-c2ccc3occ(COc4c(F)cccc4CC(=O)O)c3c2)c1F

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARD Q03181 2/20 0.38
CD274 Q9NZQ7 1/20 0.37
FFAR1 O14842 1/20 0.37
CFD P00746 4/20 0.36
PPARG P37231 1/20 0.35
PPARA Q07869 1/20 0.35
PTGER1 P34995 1/20 0.35
PTGER4 P35408 1/20 0.35
PTGER3 P43115 1/20 0.35
PTGER2 P43116 1/20 0.35
FABP4 P15090 1/20 0.35
FABP5 Q01469 1/20 0.35
PLG P00747 1/20 0.35
PLAU P00749 1/20 0.35
F11 P03951 1/20 0.35
KLKB1 P03952 1/20 0.35
F7 P08709 1/20 0.35
TPSB2 P20231 1/20 0.35
ALOX15 P16050 1/20 0.34
KDM4E B2RXH2 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29592722 1.00 PPARD (0.38) PPARDCD274FFAR1CFDPPARG
SCHEMBL23218524 0.89 ALDH2 (0.34) CFD
SCHEMBL29852951 0.89 ALDH2 (0.34) CFD
SCHEMBL29592710 0.88 CFD (0.49) PPARDCD274CFDPTGER1PTGER4
SCHEMBL23218539 0.88 CFD (0.49) PPARDCD274CFDPTGER1PTGER4
SCHEMBL23218805 0.87 CFD (0.52) PPARDFFAR1CFDPPARGPPARA
SCHEMBL29591167 0.87 CFD (0.52) PPARDFFAR1CFDPPARGPPARA
SCHEMBL29592081 0.85 CFD (0.43) PPARDCD274FFAR1CFDPTGER1
SCHEMBL23218864 0.85 CFD (0.43) PPARDCD274FFAR1CFDPTGER1
SCHEMBL23218126 0.83 CFD (0.42) PPARDCD274FFAR1CFDPTGER1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 US disclosed
CN-114502168-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-13 CN disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB PPARD 2085/4885CD274 2774/4885FFAR1 3516/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB PPARD 3096/4885CD274 4001/4885FFAR1 3234/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.